

Development of small molecule LRRK2 inhibitor for Parkinson's disease treatment

Whan In Pharm. Co., Ltd.



NEUROSCIENCE	Candidate
Product Type	Chemical Product
Indication	Parkinson's Disease
Target	LRRK2(leucine-rich repeat kinase 2)
MoA(Mechanism of Action)	Inhibition of LRRK2 (LRRK2 inhibitor) : 1) Decreases neuro-inflammation 2) Improves the mitochondrial function 3) Improves the lysosomal function
Competitiveness	<ul style="list-style-type: none"> • The compound has a unique chemical structure designed through the molecular modeling program. • The compound penetrates the blood-brain barrier and inhibits both wild/ mutant types of LRRK2 kinase. • The safety of the compound was confirmed through the early toxicity tests. (cardiotoxicity, genotoxicity, cytotoxicity, etc.)
Development Stage	Candidate
Route of Administration	Oral